Livforsakringsbolaget Skandia Omsesidigt Sells 800 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Livforsakringsbolaget Skandia Omsesidigt cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,517 shares of the biopharmaceutical company’s stock after selling 800 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Gilead Sciences were worth $1,066,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of GILD. Norges Bank bought a new position in shares of Gilead Sciences during the fourth quarter worth about $1,789,254,000. FMR LLC grew its stake in Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock valued at $3,724,306,000 after purchasing an additional 7,157,113 shares in the last quarter. GAMMA Investing LLC grew its stake in Gilead Sciences by 13,891.1% in the first quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company’s stock valued at $285,761,000 after purchasing an additional 2,532,070 shares in the last quarter. Northern Trust Corp grew its stake in Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock valued at $1,377,707,000 after purchasing an additional 2,458,954 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Gilead Sciences in the fourth quarter valued at approximately $207,340,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $113.00 on Tuesday. The stock has a market capitalization of $140.56 billion, a PE ratio of 305.41, a P/E/G ratio of 0.71 and a beta of 0.29. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The business has a fifty day moving average price of $105.41 and a two-hundred day moving average price of $101.80. Gilead Sciences, Inc. has a fifty-two week low of $62.69 and a fifty-two week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.32) EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.80%. Gilead Sciences’s dividend payout ratio is presently 66.53%.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the transaction, the chief financial officer now owns 165,674 shares of the company’s stock, valued at approximately $16,537,578.68. The trade was a 1.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the transaction, the chief executive officer now directly owns 620,268 shares of the company’s stock, valued at $68,489,992.56. This trade represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold 43,000 shares of company stock valued at $4,630,310 in the last three months. Corporate insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on GILD shares. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Royal Bank of Canada raised their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research note on Thursday, February 13th. Bank of America raised their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Finally, BMO Capital Markets lifted their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.